
Smallpox Vaccination Management of Complications

James Hargreaves, D.O.
Infectious Diseases
Altru Health System



Objectives

- Describe normal and adverse events that can follow smallpox vaccination (AES).
- Identify laboratory testing useful for evaluating rash illness.
- Review pharmacology related to medical management of AES.
- Describe infection controls for patients with AES including empiric isolation for rash illness.
- List resources to assist with management of AES and rash illness.

About the photo images

www.bt.cdc.gov/training/smallpoxvaccine/reactions/default.htm


Images courtesy of:

- Vincent Fulginiti MD
- The Estate of Henry C. Kempe MD
- NIH/Smallpox Vaccination Dilution Studies
- Centers for Disease Control and Prevention
- New England Journal of Medicine
- Logical Images, Inc

Pictures labeled from CDC are in the public domain.
All other pictures are posted with the permission of the copyright holders and may not be reproduced or used for commercial purposes without the written permission of the copyright holders.

Primary Site Reaction Smallpox Vaccine

Primary Vaccination Site Reaction




Day 4



Day 7



Day 14



Day 21

Normal Reaction Time

Day	Description
0	vaccination
3-4	papule
5-6	vesicle with erythema
8-9	pustule
<mark>12</mark> +	crusting
<u> 17 - 21</u>	scar



Normal Systemic Symptoms

- Soreness
- Intense erythema
- Malaise
- Lymphadenopathy (local)
- Myalgia, H/A, chills, nausea
- Fever

Normal Reaction Frequency

Lymphadenopathy

25 – 50%

Myalgia, H/A, chills, etc

0.3 - 37%

Fever > 37.7

2.0 - 16.0%

Normal Reactions: Variants

- Local satellite reactions (2.4 6.6%)
- Lymphangitis
- Local edema
- Viral cellulitis
 - intense inflammation surrounding papule
- Treatment: supportive

Normal Variants of Vaccine Reaction

- Local edema at vaccination site
- Lymphangitis
- Regional lymphadenopathy (nonfluctuant)
- Satellite lesions





Local Reactions

- Allergic reactions to bandage and tape adhesives
- Large primary vaccination reactions ("robust primary takes" – RPT)
- Secondary bacterial infection



Allergic reaction

Robust Primary Takes

- Normal variant (RPT)
- >3 inches of erythema with induration, pain, warmth
- Occur in 5%-15%
- Peak at day 8-10
- Resemble bacterial infection



Satellite lesions






Lymphangitis





Viral Cellulitis







Edema







Revaccination

- Typical pustule @ 6 8 days
- Major reaction more rapid evolution
- Equivocal reaction
 - allergic reaction
 - no reaction

Revaccination





Accidental Administration

- PO, IV or IMnot advised
- Follow clinically



 Autoinoculation or contact



Common

especially with primary vaccinees



- Infants and children
- Susceptible population
 - eczema
 - skin disorders with open lesions
 - inflammatory eye lesions



- Transfer of virus to another body part
- High viral load



Accidental Implantation - Diagnosis

- Appears like vaccination unless susceptible patients
 - eczema vaccinatum, keratitis, etc.



Lab not required

Accidental Implantation Treatment

- One or few
 - supportive
- Multiple or large area, or toxic
 - -VIG



Inadvertent Inoculation

- Uncomplicated lesions require no therapy, self-limited, resolve in ~3 weeks
- VIG may speed recovery if extensive or painful genital involvement
- Hand hygiene* after contact with vaccination site or contaminated material most effective prevention
- *with soap and water or alcohol hand rub

Altru Health System


Secondary Bacterial Infection

- More common among children than adults
- Usually Staph aureus or Group A beta hemolytic Streptococci
- Anaerobic and mixed infections may occur
- Evaluate with gram stain and culture
- Antibiotic therapy
 2/3/200 based on culture



Fetal Vaccinia

- Rare complication (<50 cases reported)
- usually second or third trimester
- Fetal infection spontaneous abortion
 Death usually occurs
 before birth or in perinatal
 period
- No known congenital malformations
- No known reliable intrauterine diagnostic test



Fetal Vaccinia

Clinical

- generalized vaccinia
- progressive vaccinia

Diagnosis

- H/O vaccination
- typical lesions
- Treatment
 - if viable VIG



Table 3. Rates of Complications from Vaccinia, According to Vaccination Status and Age.*

COMPLICATION	PRIMARY VACCINATION (N =650,000)				REVACCINATION (N=998,000)				
	0-4 тя	5-19 yr	≥20 YR	ALL AGES	1-4 va†	5-19 yr	⇒20 тд	ALL AGES	
	no. of events/1 million vaccinations								
Accidental infection	564	371	606	529	198	48	25	42	
Generalized vaccinia	263	140	212	242	0	10	9	9	
Erythema multiforme	209	87	3.0	165	73	2	9	10	
Eczema vaccinatum	39	35	3.0	39	0	2	5	3	
Postvaccinal encephalitis	15	9	0	1.2	0	0	5	2	
Progressive vaccinia	3	0	0	2	0	0	7	3	
Other	222	214	636	266	18	24	55	39	

^{*}Data are from a 1968 survey of 10 states.** No deaths occurred.

[†]No children under the age of one year were revaccinated.

Eczema Vaccinatum

- Generalized spread in patient with eczema or true atopic dermatitis, or a history of eczema or atopic dermatitis
- Severity independent of the activity
- Severe cases among contacts



Eczema Vaccinatum clinical

- Skin lesions may be papular, vesicular, or pustular
- May occur anywhere on the body
- Predilection for areas of previous atopic dermatitis
- Patients often severely ill



Sibling contact

Eczema Vaccinatum clinical

- May resemble septic shock
- Can be lethal
- Bacterial superinfections
- Abscess
- Resolve with extensive scarring



Eczema
vaccinatum in
contact to recently
vaccinated child.

- Recovered without sequelae or permanent ocular damage.



Eczema Vaccinatum diagnosis

- Characteristic lesions
 - H/O vaccine or contact with a vaccinee
- Lab may be required to differentiate
 - HSV PCR
- Septic work up



Eczema Vaccinatum treatment

Management

- Hemodynamic support
- Meticulous skin care
- Early treatment with VIG
- Treatment of secondary bacterial or fungal infections as needed





Post-Vaccinial Encephalitis

- Usually affects primary vaccinees
- Meningoencephalitis
- Cause unknown autoimmune theory
- Variety of CNS signs (e.g., ataxia, confusion, paralysis, seizures, or coma)
- 15%-25% die, 25% develop neurological sequelae
- Occurred 3-12 cases per million primary vaccinations

Post-Vaccinial Encephalitis

- Diagnosis of exclusion
 - HSV, EBV, VZV, enterovirus, arbovirus
- CSF may have increased opening pressure, lymphocytosis, elevated protein
- Treatment is supportive
- VIG not effective
- Anticonvulsive therapy and intensive care may be required

Erythema Multiforme

- May present as macules, papules, urticaria, or bulls-eye lesions
- Usually appears within 10 days
- Does not progress
- Does not contain vaccinia virus



Erythema Multiforme

- Increasing frequency@ younger age
 - < 4 164 cases/million</p>
 - .20 30.3 cases/million
- Most erythematous, pruritic, and benign



Erythema Multiforme

- Mild few patches and blotches
 - urticaria, vesicles, and/or pustules
- Extensive most of body
- Severe Stevens-Johnson
 2/3/2003
 Syndrome



Erythema Multiforme diagnosis

- Rash
 - H/O vaccination
- Vesicles and pustules
 - Difficult to differentiate
 - generalized vaccinia
 - accidental implantation
 - occurs later
 - devoid of massive erythema
 - may require viral studies



Erythema Multiforme treatment

- Pruritis antihistamine
- Skin
 - no special care except
 - Stevens-Johnson
 - hospitalize
- VIG ineffective



Erythema Multiforme Ankle, Day 8



Erythema Induration from Pustule to Elbow



Rashes Following Smallpox Vaccine

- Flat, erythematous, macular, or urticarial lesions
- Usually do not become vesicular
- Do not appear to involve viral multiplication or systemic dissemination
- Occur approximately 10 days after vaccination
- Resolve spontaneously within 2 to 4 days

Generalized Vesicular Rash, Day 11



Generalized, Flat, Erythematous Rash, Leg, Day 13



Localized Vesicular Rash on Hands



Localized Papular Rash, Elbow, Day 18



Generalized Vaccinia

- Vesicles or pustules appearing on normal skin distant from the vaccination site
- Often accompanied by fever, headache, and myalgias
- Usually occur 6-9 days after vaccination



Generalized Vaccinia

- Generally benign
- Confused with eczemavaccinatum
- Pathogenesis
 - viremia
 - skin only target
 - -? Humoral defect



Generalized Vaccinia clinical

- Skin lesion
 - similar to vaccine site except:
 - smaller
 - more rapid evolution
 - any part of the body
 - can be recurrent
 - every 4 6 weeks
 - as long as 1 year



Generalized Vaccinia Differential Diagnosis

- Erythema multiforme
 - not umbilicated
 - doesn't resemble vaccination
- Eczema vaccinatum
 - H/O eczema
 - distribution of eczema



Generalized Vaccinia Differential Diagnosis

- Inadvertent inoculation at multiple sites
- Early progressive vaccinia
- Disseminated herpes
- Severe varicella
 - -superficial vesicles
- Smallpox



Generalized Vaccinia

- Treatment
 - usually none
 - if extensive or recurrent then VIG
 - Work-up humoral defects



Generalized Vaccinia

- Generally self-limited, usually no treatment
- VIG considered for recurrent disease or severe disease
- Lesions contain vaccinia



Progressive Vaccinia

- Often life-threatening
- Other names
 - vaccinia necrosom
 - vaccinia gangrenosa
 - disseminated vaccinia
- Rare (1 / million primary vaccinees)



Progressive Vaccinia

- Primary vaccination does not heal
- Progresses to ulcerative lesion, often with central necrosis
- Little or no inflammation at the site and generally little pain
- Virus continues to spread locally and through viremia



Progressive Vaccinia Who's susceptible?

- Immunodeficiency– esp CMI
- HIV
- Cancer
- Organ transplant
- Immunomodulating drugs



Progressive Vaccinia pathogenesis

- Cell to cell spread
- Necrotic skin centrally
 - advancing edge
- Viremia
 - metastatic skin sites
 - evolve similarly
- Secondary bacteria, fungal, or parasitic
 (PCP)



Progressive Vaccinia clinical

- Primary vaccine site doesn't heal
- Ulcerative and/or pustular lesions with central necrosis
- Circumferential expansion
- Viremia cause satellite lesions



Progressive Vaccinia clinical

- No lymphadenopathy
- No splenomegaly
- Extensive tissue destruction
- Superinfections
- Sepsis, DIC
- Unmatched lymphocytes -GVHD



Progressive Vaccinia (vaccinia necrosum) in Patient with Chronic Granulocytic Leukemia





Progressive Vaccinia differential diagnosis

- Severe bacterial infection
 - severe inflammation
 - No H/O CMI
- Smallpox
- Chickenpox
 - lack vaccine site
 - superficial
 - various stages of rash
- Disseminated HSV



Progressive Vaccinia testing

- Rash and fever algorithm
- Consult Public Health & ID
- HSV PCR
- VZV PCR
- Viral cultures
- Stains
- Immunological work-up

2/3/2002 HIV, flow cytometry etc



Progressive Vaccinia

- Requires aggressive therapy with VIG
 - up to 10 ml/kg
- Antiviral therapy?
 - Cidofovir
 - Ribavirin
- Surgical debridement?
 - Debulk viral load



Ocular Vaccinia

- May present as blepharitis, conjunctivitis, keratitis, iritis, or combination
- Treatment may include topical ophthalmic antiviral agents and VIG



Vaccinia keratitis

- Central grayish, disciform corneal lesion
- Progresses to deeper ring-like structure



Vaccinia keratitis

- Ophthalmologist referral
- Slit lamp
- Avoid VIG
- Vidarabine
- Trifluribine
- Acyclovir
- Combination antiviral nucleoside + IFN speeds healing



Chickenpox

Inversion Concentrate (Vancoula)











DIFFERENTIATING CHICKINGON FROM SMALLFOX

Chickenges (revisely) is the most likely condition to be confound with


In chickenpoor

- a No or sold produces
- a Laurence and coperficial resolving. "Absorbings on a room parts" (less phone or treat-
- a Laminor against in comparison any one part of the body there are feature in different stages (pagelos, malches, cramb)
- . Correspond destribution: greatest concentration of feature on the mork, forest lesions on detail exercentials. Play itsoftes the facultosity. Occasionally entire body manife effected.
- After house appear on the house manet.
- a Patients tomby tomby or marketed.
- . Republications: Indiana analise from maculas or property or machine or cream specific (PGM Naveril)
- Patron and soline repelly investigated
- Proteon Section reduction Security of controller on controller construction
- 10-60% result on engineers to chindrengias or droughts 10-21 days before monthly

Marcifolds: In Nation Place in Indian Place in Local & Nation of Participates (National Papersons). House, Scalable of Salabara, National Analysis of Salabara

EVALUATING PATIENTS FOR SMALLPOX

ACUTE GENERALIZED VESICULAR OR PUSTULAR RASH RUNESS PROTOCOL



RISK OF SHALLPOX

High Rid of Smallest in Report Immediately.

- 1. Publish produces (Melloud below) AND
- 1. Country smulpon better (defend below & photo at top right). 1999
- 3. Casions in some stage of development (defined before)

Photograph Bids of Smallpoor in Object Contracts

- 1. Policile produces (defined below)
- 3. One other many analysis oritorius (defined below)
- 1. Publish produces (Melicul Salars)
- 3: 34 Percent sensigner extends (defined below)

have their of broadpase to Manage as Christially Indicated

- 1. No littelle prodrame
- 1. Betelle gredness SAID
- 3. 48 MINUS smallpox criteria (defined below)

MAJOR SHALLPOX CRITERIA.

- PERSONAL PRODUCEDS: Assuring 6-4 days before each arrang from \$100.70. and at least one of the following: prescrution, bendache, backedie, chills, meeting or severe shakement pain.
- A CLASSIC SHALLPOX URSOMS incremed broken must will or currentled webbs or pumbs, as they works, below may become unfollowed
- ALESSONS IN SAME STAGE OF DEVELOPMENT: or my owners of the budy (e.g., the face, or area) of the feature are in the same stage of directoprison. Securities without it is penaled

There have been no metandly according costs of analysis asymbols in the world seem 1977. A high rain case of smallpowin a public health and marked and the second

1	Hospital Inflection Control		6	=	\equiv
1		health department	1	=	=
1		health department	1	:=	=


MINOR SHALLPOX CRITERIA.

- a Contribute distribution greatest concentration of feature on flow and should
- wiffing feature on the analysecons/palets, how or forestree
- «Patient assesses tools or market fi
- affine exclusive feature profes from mander to papers in punish over days Send rouge born 1-3 deed
- adjustment on the paints and solite.

Descriptions of Mary To and Stones Street,

Concessor than September Concessor, and Performance

Smallpox (variola)




















Corescon Concernova must Michie be Constate with Sinklance.				
Comprise	Common Comm			
National Systems (Michigan with remarks committee)	Place common in children 419 pages, children analysis our four is not produced.			
Dissentated herges some	Interpretation of the Control of the			
Implement Army Implement Army	Planty colored crisical plaques with hallow are classed but may legal on marries; regulated rate dissertational main particular protectly and if			
Drug angelors	Reposure true medications; rach other generalised			
Compan dermation	fulfrig corner with possible of organic reals of our foundation partners organizing contents content.			
Stydens indifferent enter	Sp Marie Samuelater			
Systems multiforms (not floress principal systems)	Pager form involves museum monthsystem & conjunctions; years for singer features or mostles.			
Descriptive of Park, Fore and Plants Masse	Commerce & Mal Notes & cost place pages 1 2 days before cash month, framer being the confinement for month one place of page continue for all the cost of propheror development describ, free, second, or disconnected.			
Demonstrated Inspectingles	Common militarique trade from surbally, consistency spectrum from			
Stations, Francis Intern (Incl. Beau)	Noting is a major symptom pushes in our Mirch & is either- wise and			
Malacan caraginan	Ply Sucritics is incurring road prices			
the same between these parts and the same regularity and produce and				

The Person is not a desired in column 2 to 100 to 1

Evaluating Patients for Smallpox



Rapid Tests suitable for VSV (smallpox rule-out)

- Tzanck Smear local cytology lab
- DFA VZV
 - done same day received at NDPHL
- Real time PCR

RULE IN VARICELLA

ND Public Health Lab (NDPHL)

- Contact: Mike Trythall or Bonna Cunningham
- Phone: 701-328-5262
- Collection kits/shipping containers available within 30 days to NDLRN Level A Laboratories.
 - 1) DFA Screen for HSV, enterovirus and varicella [Touch prep slides in collection kit.]
 - 2) RT-PCR for vaccinia send to NDPHL [24 hour TAT with consultation.]
 - 3) Culture [M4 culture transport in collection kit.]
 - 4) Smallpox confirmation sent to LRN Variola Regional Labs [Contact NDPHL for assistance.]

Altru Health System

Sample requirements for Poxvirus DNA

- Lesion "roofs" and crusts
- Vesicular fluids (touch prep)
- Biopsy, autopsy
- 10 ml clot tube; 5 ml EDTA

www.bt.cdc.gov/agent/smallpox/training/webcast/dec2002/files/laboratory-module.ppt www.bt.cdc.gov/labissues/PackagingInfo.pdf www.bt.cdc.gov/agents/smallpox/response-plan/files/guide-d.pdf

Lab methods for confirmation of orthopoxvirus diagnostics

- PCR DNA
- Electron microscopy
- Histopathology
- Viral Culture

Vaccinia Immune Globulin

- Immunoglobulin fraction of plasma from persons vaccinated with vaccinia vaccine
- Indications:
 - eczema vaccinatum
 - progressive vaccinia
 - severe generalized vaccinia
- Limitations:
 - no role in smallpox
 - post-vaccinial encephalitis

Vaccinia Immune Globulin must weigh risk and benefits

- Contraindications
 - Vaccinial keratitis
 - increase scarring in rabbits
 - Serious allergy to human immunoglobulin products
 - Selective IgA deficiency
 - thimerosal allergy
- Pregnancy category C
- Lactation unknown if in breast milk

Vaccinia Immune Globulin (IV) adverse effects

- Infusion
 - minimize with slow rate
- moderate toxicity
 - arthralgia, headaches, myalgias, fever, chills, pruritis etc.
- severe toxicity
 - anaphylaxis (IM or IV)
 - renal failure (IV)
- 2/3/2003 aseptic meningitis (IV)

Vaccinia Immune Globulin IV formulation

- Refer to package guidelines
- starting dose 0.6 ml/kg = 6000U/kg = 100 mg/kg (adult and peds)
- starting infusion rate 0.01 0.02 mL/kg/min, gradually increase to 0.08 mL/kg/min
- repeat every 2 3 days if needed

Vaccinia Immune Globulin IM formulation

- Older method, IV should be used first
- Dose
 - -0.6 ml / kg IM
 - Buttock or anterolateral thigh
 - If dose exceeds 10 ml, divide into > 2 sites
 - DO NOT GIVE IV
 - May be repeated if needed

Vaccinia Immune Globulin

- Call state Public Health
- Consult with local ID doctor

Cidofovir (Vistide)

- Nucleotide analogue of cytosine
- Broad spectrum of activity against herpesviruses
- Activity against orthopoxviruses in cellbased and animal models
 - active in vitro against variola
 - active in animals against vaccinia infections
- Currently approved for treatment of CMV retinitis in persons with AIDS
- Available for treatment of vaccinia under IND

Cidofovir Adverse Events

- Renal toxicity
 - Proteinuria
 - irreversible renal failure
- Neutropenia
- Anterior uveitis/iritis
- Metabolic acidosis
- Possible carcinogenicity and teratogenicity
- Probenicid adverse events
 - headache, nausea, vomiting, hypersensitivity, hemolytic anemia, hepatic necrosis, gout, uric acid stones

Cidofovir Indications

- Second line treatment of complications of smallpox vaccination
- Use if patient fails to respond to VIG treatment
- Consult with CDC before use under IND
- Manufacturer recommends use with probenicid

Ribavirin

- IV ribavirin
 - Not commercially available
 - Effective in 1 case of progressive vaccinia

Trifluridine (Viroptic)

- Pyrimidine nucleoside
- indicated HSV keratoconjunctivitis
- pregnancy risk C
- lactation unknown if secreted
- adverse reactions:
 - burning, stinging 1 10%
 - -<1%: hyperemia, edema, keratopathy, keratitis,inc intraocular pressure</p>

Infection Controls

for the patient with adverse event after smallpox vaccination

Reaction	Control
Less serious – normal vaccination varients, few satellite lesions, inadvertant	Contact Precautions Add Airborne precautions if
innoculation	oral/nasal lesions
Erythema multiforme	Standard Precautions
Vaccinia encephalitis	Contact and Airborne Precautions, until proven vaccina— then Standard
More Serious- generalized vaccinia, eczema vaccinatum, progressive vaccinia, fetal vaccinia	Contact and Airborne Precautions
Keratitis	Contact Precautions
Secondary Bacterial Infection	Contact Precautions

Empiric Isolation

- Screen for history of Smallpox vaccination or contact with vaccinated
 - may be unaware of an inadvertent exposure
- Meningoencephalitis
 - Droplet Isolation
- Vesicular or pustular rash illness
 - Airborne and Contact Isolation

Infection Controls

Contact Isolation

- Standard precautions
- Private room
- Hand hygiene with antimicrobial soap or alcohol
- Gloves
- Gowns
- Dedicated equipment

2/3/200 Good housekeeping

Airborne Isolation

- Standard precautions
- Negative pressure room
- N95 masks

Altru Health System

Infection Control-staffing

For routine assignment, choose HCW in this order

Vaccinated HCW with "take" <3 years. Wear N95 mask.

Hx of prior vaccination and no personal contraindications for smallpox vaccination. Wear N95 mask.

No prior smallpox vaccination and no personal contraindications for smallpox vaccination. Wear N95 mask.

In emergency situations when above not available

HCW with a contraindication in household member only. Scrupulous infection control precautions including N95 mask

HCW with a personal contraindication. <u>Scrupulous</u> infection control precautions including N95 mask

Resources

- www.bt.cdc.gov
- State ND
 - Health Dept 1-800-472-2180
 - Disease Control in Bismarck 701-328-2378
- CDC
 - 770-488-7100 if unable to call State PH
 - Smallpox Clinician Info Line 877-554-4625

Resources

- State Health Officers
 - Terry Dwelle, MD
 - Steve Pickard, MD

- Physicians
 - Shamoon Ahmed, MD
 - Paul Carson, MD
 - James Hargreaves, DO
 - Tze Shien Lo, MD
 - Kent Martin, MD
 - Roberto Patron, MD
 - Vinod Seith, MD
 - Raymond Smego, MD
 - Robert Tight, MD